Peter Heerma Sells 1,771 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 1,771 shares of the business’s stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $37,279.55. Following the transaction, the insider now owns 128,215 shares in the company, valued at $2,698,925.75. The trade was a 1.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Peter Heerma also recently made the following trade(s):

• On Tuesday, February 11th, Peter Heerma sold 3,074 shares of Travere Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $76,850.00.

Travere Therapeutics Stock Up 1.2 %

Shares of NASDAQ:TVTX opened at $21.41 on Tuesday. The stock’s 50-day moving average price is $18.09 and its two-hundred day moving average price is $18.77. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 12-month low of $6.01 and a 12-month high of $25.29. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -5.22 and a beta of 0.88.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.08. The firm had revenue of $81.73 million during the quarter, compared to the consensus estimate of $77.44 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm’s quarterly revenue was up 83.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.76) earnings per share. On average, research analysts forecast that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Evercore ISI increased their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Scotiabank restated an “outperform” rating on shares of Travere Therapeutics in a report on Friday, April 11th. Guggenheim restated a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research note on Monday, April 14th. Bank of America upped their target price on shares of Travere Therapeutics from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Finally, Stifel Nicolaus upped their target price on Travere Therapeutics from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $31.79.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently made changes to their positions in TVTX. Rock Springs Capital Management LP increased its stake in Travere Therapeutics by 6.2% during the 4th quarter. Rock Springs Capital Management LP now owns 4,973,649 shares of the company’s stock worth $86,641,000 after buying an additional 289,173 shares during the period. Renaissance Technologies LLC increased its holdings in Travere Therapeutics by 28.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company’s stock worth $41,974,000 after purchasing an additional 534,500 shares during the last quarter. Driehaus Capital Management LLC raised its position in shares of Travere Therapeutics by 608.1% in the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company’s stock valued at $38,637,000 after purchasing an additional 1,904,733 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Travere Therapeutics by 36.7% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company’s stock worth $37,875,000 after buying an additional 583,836 shares in the last quarter. Finally, Emerald Advisers LLC raised its holdings in Travere Therapeutics by 8.4% in the fourth quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company’s stock valued at $37,030,000 after acquiring an additional 165,085 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.